View:

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported):  July 31, 2019

 

NABRIVA THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-37558

 

Not Applicable

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification
No.)

 

25-28 North Wall Quay,
IFSC, Dublin 1, Ireland

 

Not Applicable

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (610) 816-6640

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which
registered

Ordinary Shares, nominal value $0.01 per share

 

NBRV

 

The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 


 

Item 5.07              Submission of Matters to a Vote of Security Holders.

 

At the Annual General Meeting of Shareholders of Nabriva Therapeutics plc (the “Company”) held on July 31, 2019, the Company’s shareholders voted on the following proposals:

 

(1)                                 The Company’s shareholders elected the following nominees to serve as directors until the 2020 Annual General Meeting of Shareholders.

 

Name

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

Daniel Burgess

 

33,676,568

 

114,381

 

123,320

 

22,090,266

 

Theodore Schroeder

 

33,739,046

 

111,944

 

63,279

 

22,090,266

 

Colin Broom, M.D.

 

33,694,565

 

91,384

 

128,320

 

22,090,266

 

Carrie Bourdow

 

33,641,071

 

143,578

 

129,620

 

22,090,266

 

Mark Corrigan, M.D.

 

33,673,043

 

118,906

 

122,320

 

22,090,266

 

Charles A. Rowland, Jr.

 

33,669,160

 

116,789

 

128,320

 

22,090,266

 

George H. Talbot, M.D.

 

33,562,181

 

229,168

 

122,920

 

22,090,266

 

Stephen Webster

 

33,670,278

 

111,817

 

132,174

 

22,090,266

 

 

(2)           The Company’s shareholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 and authorized, in a binding vote, the Company’s board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration.

 

For

 

Against

 

Abstain

 

54,990,376

 

635,724

 

378,435

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NABRIVA THERAPEUTICS PLC

 

 

Date: August 5, 2019

By:

/s/ Gary Sender

 

 

Gary Sender

 

 

Chief Financial Officer

 

3